Global Topical Drugs Market (2022 to 2030) – Size, Share & Trends Analysis Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Topical Drugs Market Size, Share & Trends Analysis Report by Type (Semi-solid, Liquid), by Route Of Administration (Dermal, Ophthalmic), by End-use (Burn Centers, Hospitals & Clinics), by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The global topical drugs market size is expected to reach USD 217.79 billion … [Read more…]

AscellaHealth Family of Companies is Founding Sponsor of Inaugural Gene Therapy and Specialty Pharmacy Awareness Month, September 2022

BERWYN, Pa.–(BUSINESS WIRE)–The AscellaHealth Family of Companies, including AscellaHealth, a global healthcare and specialty pharmacy solutions company, and subsidiaries Optime Care and Terebellum, announces its founding sponsorship of the inaugural Gene Therapy and Specialty Pharmacy Awareness Month, September 2022, which was accepted for inclusion in the annual Calendar of Health Observances & Recognition Days, published … [Read more…]

Long COVID Outpaces Diabetes in 2022 Employer Health Care Costs, Nomi Health Research Finds

Diagnoses on the rise as U.S. employers see sharp medical spend increases OREM, Utah–(BUSINESS WIRE)–As COVID-19 cases continue gripping the country, skyrocketing medical costs as a result of long COVID pose a significant financial risk not just for patients, but also for buyers of care in the public and private sectors. According to results of … [Read more…]

HighTide Therapeutics Announces Early Completion of Enrollment in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus

SHENZHEN, China & ROCKVILLE, Md.–(BUSINESS WIRE)–HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biotechnology company focused on the development of innovative multi-functional therapeutics to address the complex pathophysiology of metabolic and digestive diseases, announced that enrollment was completed ahead of schedule in a Phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus … [Read more…]

Ulcerative Colitis Market Forecasts, Epidemiology & Pipeline Analysis 2022-2027: Focus on 8 Major Markets – United States, France, Germany, Italy, Spain, United Kingdom, China, and Japan – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ulcerative Colitis Market Forecast – Epidemiology & Pipeline Analysis 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The ulcerative colitis epidemiology provides insights into the historical and current patient pools and forecasted trends for eight (8MM) major countries. The ulcerative colitis segment covers the historical and forecasted epidemiology data in the US, EU5 … [Read more…]

 Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update

 Conference Call to be Held on Thursday, September 8, 2022 at 4:00 p.m. (EDT) DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the closing of its rights offering and the final results thereof. Navidea received aggregate gross … [Read more…]

Nexa3D Expands its Digital Dentistry Customer Reach

Nexa3D creates key dental leadership roles in Europe, focused on expanding access to the latest dental technology Bracon Dental joins Nexa3D Dental reseller network, bringing ultrafast dental 3D printing capabilities to the United Kingdom First desktop XiP installation in a dental business signals rising demand for chair-side 3D printing capabilities   VENTURA, Calif.–(BUSINESS WIRE)–Ultrafast industrial … [Read more…]

OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain. Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market potential. IND filing on OK-101 to treat DED planned for Q4 2022, with first human trial designed as Phase 2 trial planned to begin in Q1 … [Read more…]

CareView Communications Releases Software Version 5.6

LEWISVILLE, Texas–(BUSINESS WIRE)–CareView Communications, Inc. (“CareView” or the “Company”) (OTCQB: CRVW), an information technology provider to the healthcare industry, today announced its latest updates to its CareView Patient Safety System®, Version 5.6, which includes system integration with Vocera and Hillrom, paving the way for a new paradigm in clinical workflow management. With these integrations, safety … [Read more…]

Healee Lands $2M to Grow Customizable Telehealth Solution in the U.S.

New funding round led by Nina Capital enables Healee to empower unique digital health models and accelerate telehealth adoption TAMPA, Fla.–(BUSINESS WIRE)–#custom—Healee, providing highly configurable digital health technology, announced today that it has raised $2M in a seed round led by Nina Capital, with the participation of Calm/Storm Ventures, KAYA VC and existing investor Eleven … [Read more…]